An improved whole cell pertussis vaccine with reduced content of endotoxin

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 2, 2013, Pages 339-348

  Dias, Waldely Oliveira ^a   Van Der Ark, Arno A J ^b   Sakauchi, Maria Aparecida ^a   Kubrusly, Flavia Saldanha ^a   Prestes, Ana Fabiola R O ^a   Borges, Monamaris Marques ^a   Furuyama, Noemi ^a   Horton, Denise S P Q ^a   Quintilio, Wagner ^a   Antoniazi, Marta ^a   Kuipers, Betsy ^b   Van Der Zeijst, Bernard A M ^b   Raw, Isaias ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Bordetella pertussis; Endotoxicity; Immunogenicity; Lypo oligosaccharide; Pertussis vaccines; Reactogenicity; Safety

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; ENDOTOXIN; LIPOOLIGOSACCHARIDE; PERTUSSIS VACCINE; UNCLASSIFIED DRUG; WHOLE CELL PERTUSSIS VACCINE; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STABILITY; ENDOTOXEMIA; EXTRACTION; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; T LYMPHOCYTE; TOXICITY TESTING; ANIMAL; CHEMISTRY; IMMUNOLOGY; ISOLATION AND PURIFICATION; RABBIT;

ANIMALS; DRUG STABILITY; ENDOTOXINS; FEMALE; MICE; PERTUSSIS VACCINE; RABBITS; VACCINE POTENCY;

EID: 84874698146     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.22847     Document Type: Article

References (42)

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, et al.; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010; 375:1969-87; PMID:20466419; http://dx.doi.org/10.1016/S0140-6736(10)60549- 1.
2. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003; 22:22-7; PMID:12544404; http://dx.doi.org/10.1097/00006454-200301000-00009. (Pubitemid 36091773)
3. Cherry JD. The science and fiction of the "resurgence" of pertussis. Pediatrics 2003; 112:405-6; PMID:12897292; http://dx.doi.org/10.1542/ peds.112.2.405.
4. Cherry JD. Epidemiological, clinical, and laboratory aspects of pertussis in adults. Clin Infect Dis 1999; 28(Suppl 2):S112-7; PMID:10447028; http://dx.doi.org/10.1086/515058. (Pubitemid 29270379)
5. Cherry JD, Olin P. The science and fiction of pertussis vaccines. Pediatrics 1999; 104:1381-3; PMID:10585991; http://dx.doi.org/10.1542/peds.104. 6.1381.
6. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334:349-55; PMID:8538705; http://dx.doi.org/10.1056/NEJM199602083340602. (Pubitemid 26049587)
7. Greco D, Salmaso S, Mastrantonio P, Giuliano M, Tozzi AE, Anemona A, et al.; Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-8; PMID:8538704; http://dx.doi.org/10.1056/NEJM199602083340601. (Pubitemid 26053148)
8. Sato Y, Kimura M, Fukumi H. Development of a pertussis component vaccine in Japan. Lancet 1984; 1:122-6; PMID:6140441; http://dx.doi.org/10.1016/S0140- 6736(84)90061-8. (Pubitemid 14217548)
9. David S, Vermeer-de Bondt PE, van der Maas NA. Reactogenicity of infant whole cell pertussis combination vaccine with or without simultaneous pneumococcal vaccine in the Netherlands. Vaccine 2008; 26:5883-7; PMID:18775463; http://dx.doi.org/10.1016/j.vaccine.2008.07.105.
10. WHO Publication. Pertussis vaccines: WHO position paper-recommendations. Vaccine 2011; 29:2355-6; PMID:21129396; http://dx.doi.org/10.1016/j.vaccine. 2010.11.059.
11. Martins RdeM, Camacho LA, Marcovistz R, Noronha TG, Maia MdeL, dos Santos EM, et al. Immunogenicity, reactogenicity and consistency of production of a Brazilian combined vaccine against diphtheria, tetanus, pertussis and Haemophilus influenzae type b. Mem Inst Oswaldo Cruz 2008; 103:711-8; PMID:19057823; http://dx.doi.org/10.1590/S0074-02762008000700014.
12. Geurtsen J, Vandebriel RJ, Gremmer ER, Kuipers B, Tommassen J, van der Ley P. Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines. Microbes Infect 2007; 9:1096-103; PMID:17644385; http://dx.doi.org/10.1016/j.micinf.2007. 04.015. (Pubitemid 47284943)
13. Raw I, Kubrusly FS, Dias WO, Esteves MI, Furuyama N, Horton DSPQ, et al. inventors; Fundacao Butantan, assignee. Process for Obtention of New Cellular Pertussis Vaccine. WO/2006/002502.2006.
14. Redhead K, Seagroatt V. The effects of purified components of Bordetella pertussis in the weight gain test for the toxicity testing of pertussis vaccines. J Biol Stand 1986; 14:57-65; PMID:2870067; http://dx.doi.org/10.1016/ S0092-1157(86)80009-9. (Pubitemid 16107447)
15. Geurtsen J, Steeghs L, Hamstra HJ, Ten Hove J, de Haan A, Kuipers B, et al. Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis. Infect Immun 2006; 74:5574-85; PMID:16988232; http://dx.doi.org/10.1128/IAI.00834-06. (Pubitemid 44484540)
16. Verwer CM, van der Ark A, van Amerongen G, van den Bos R, Hendriksen CF. Reducing variation in a rabbit vaccine safety study with particular emphasis on housing conditions and handling. Lab Anim 2009; 43:155-64; PMID:19116295; http://dx.doi.org/10.1258/la.2008.007134.
17. Mielcarek N, Debrie AS, Raze D, Bertout J, Rouanet C, Younes AB, et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006; 2:e65; PMID:16839199; http://dx.doi.org/10.1371/ journal.ppat.0020065.
18. Heipieper HJ, Neumann G, Cornelissen S, Meinhardt F. Solvent-tolerant bacteria for biotransformations in two-phase fermentation systems. Appl Microbiol Biotechnol 2007; 74:961-73; PMID:17262209; http://dx.doi.org/10.1007/ s00253-006-0833-4. (Pubitemid 46434769)
19. Leef M, Elkins KL, Barbic J, Shahin RD. Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med 2000; 191:1841-52; PMID:10839801; http://dx.doi.org/10.1084/jem.191.11.1841. (Pubitemid 30390348)
20. Souza Matos DC, Marcovistz R, Cabello PH, Georgini RA, Sakauchi D, da Silva LL. Immunogenicity test of tetanus component in adsorbed vaccines by toxin binding inhibition test. Mem Inst Oswaldo Cruz 2002; 97:909-13; PMID:12386721; http://dx.doi.org/10.1590/S0074-02762002000600030. (Pubitemid 135745947)
21. Sonobe MH, Trezena AG, Guilhen FB, Takano VL, Fratelli F, Sakauchi D, et al. Determination of low tetanus or diphtheria antitoxin titers in sera by a toxin neutralization assay and a modified toxin-binding inhibition test. Braz J Med Biol Res 2007; 40:69-76; PMID:17224998; http://dx.doi.org/10.1590/S0100- 879X2007000100009. (Pubitemid 46117720)
22. Higashi HG, Luna E, Precioso AR, Vilela M, Kubrusly FS, Dias WO, et al. Acellular and "low" pertussis vaccines: adverse events and the role of mutations. Rev Inst Med Trop Sao Paulo 2009; 51:131-4; PMID:19551286; http://dx.doi.org/10.1590/S0036-46652009000300002.
23. Geurtsen J, Banus HA, Gremmer ER, Ferguson H, de la Fonteyne-Blankestijn LJJ, Vermeulen JP, et al. Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol 2007; 14:821-9; PMID:17494641; http://dx.doi.org/10.1128/CVI. 00074-07.
24. van Straaten I, Levels L, van der Ark A, Thalen M, Hendriksen C. Toxicity and immunogenicity of pertussis whole cell vaccine in one animal model. Dev Biol (Basel) 2002
25. Mills KHG. Immunity to Bordetella pertussis. Microbes Infect 2001; 3:655-77; PMID:11445452; http://dx.doi.org/10.1016/S1286-4579(01)01421-6.
26. Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L, et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998; 93:1-10; PMID:9536112; http://dx.doi.org/10.1046/j.1365-2567.1998.00401.x. (Pubitemid 28133089)
27. Perdomo-Morales R, Pardo-Ruiz Z, Spreitzer I, Lagarto A, Montag T. Monocyte activation test (MAT) reliably detects pyrogens in parenteral formulations of human serum albumin. ALTEX 2011
28. Tsai CM, Frasch CE, Rivera E, Hochstein HD. Measurements of lipopolysaccharide (endotoxin) in meningococcal protein and polysaccharide preparations for vaccine usage. J Biol Stand 1989; 17:249-58; PMID:2477374; http://dx.doi.org/10.1016/0092-1157(89)90017-6. (Pubitemid 19219369)
29. Ibsen P, Moller S, Heron I. Lipopolysaccharides in a traditional pertussis vaccine. J Biol Stand 1988; 16:299-309; PMID:2904442; http://dx.doi.org/10.1016/0092-1157(88)90018-2.
30. Higgins SC, Jarnicki AG, Lavelle EC, Mills KH. TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol 2006 177:7980-9; PMID:17114471. (Pubitemid 44846315)
31. Geurtsen J, Fransen F, Vandebriel RJ, Gremmer ER, de la Fonteyne-Blankestijn LJ, Kuipers B, et al. Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccineinduced immune responses. Vaccine 2008; 26:899-906; PMID:18207288; http://dx.doi.org/10.1016/j.vaccine.2007.12.012.
32. Zorzeto TQ, Higashi HG, da Silva MT, Carniel EdeF, Dias WO, Ramalho VD, et al. Immunogenicity of a whole-cell pertussis vaccine with low lipopolysaccharide content in infants. Clin Vaccine Immunol 2009; 16:544-50; PMID:19261771; http://dx.doi.org/10.1128/CVI.00339-08.
33. Raw I, Kubrusly FS, Iourtov D, et al. Method to obtain monophosphoryl lipid A from Bordetella pertussis as a by-product of cellular pertussis vaccine. Patent deposited (ed. INPI). Brazil
34. Quintilio W, Kubrusly FS, Iourtov D, Miyaki C, Sakauchi MA, Lucio F, et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 2009; 27:4219-24; PMID:19393709; http://dx.doi.org/10.1016/j.vaccine.2009.04.047.
35. Thalen M, van der Ark A, van den Ijssel J, van Straaten I, Jansen D, Beuvery C, et al. Improving the cellular pertussis vaccine: increased potency and consistency. Vaccine 2008; 26:653-63; PMID:18155325; http://dx.doi.org/10. 1016/j.vaccine.2007.11.047.
36. Baart GJ, Zomer B, de Haan A, van der Pol LA, Beuvery EC, Tramper J, et al. Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes. Genome Biol 2007; 8:R136; PMID:17617894; http://dx.doi.org/10.1186/gb-2007-8-7- r136.
37. Tirsoaga A, El Hamidi A, Perry MB, Caroff M, Novikov A. A rapid, small-scale procedure for the structural characterization of lipid A applied to Citrobacter and Bordetella strains: discovery of a new structural element. J Lipid Res 2007; 48:2419-27; PMID:17703058; http://dx.doi.org/10.1194/jlr. M700193-JLR200. (Pubitemid 350058753)
38. Park CY, Jung SH, Bak JP, Lee SS, Rhee DK. Comparison of the rabbit pyrogen test and Limulus amoebocyte lysate (LAL) assay for endotoxin in hepatitis B vaccines and the effect of aluminum hydroxide. Biologicals 2005; 33:145-51; PMID:16055344; http://dx.doi.org/10.1016/j.biologicals.2005.04.002.
39. Kaaijk P, van der Ark AA, van Amerongen G, van den Dobbelsteen GP. Nonclinical vaccine safety evaluation: advantages of continuous temperature monitoring using abdominally implanted data loggers. J Appl Toxicol 2012 2012:8; PMID:22407801.
40. World Health Organization. Recommendations for whole-cell pertussis vaccine. WHO Technical Report Series -Annex 6, 2007 (941): 314-316.
41. Roduit C, Bozzotti P, Mielcarek N, Lambert PH, del Giudice G, Locht C, et al. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis. Infect Immun 2002; 70:3521-8; PMID:12065491; http://dx.doi.org/10.1128/IAI.70. 7.3521-3528.2002. (Pubitemid 34665988)
42. Bozzola JJ, Russel LD. Specimen preparation for transmission electron microscopy. In: Jones C (ed). Electron Microscopy: principles and techniques for biologists. 2th ed. Sudbury: Jones and Bartlett Publishers, 1999:16-48.